These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31556223)

  • 21. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
    Okui D; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
    Nagaoka Y; Tanaka Y; Yoshimoto H; Suzuki R; Ryu K; Ueda M; Akiyama M; Nagai M; Miyaoka Y; Kanda E; Iwai S; Nagaoka M; Kanno Y
    Hemodial Int; 2018 Jul; 22(3):388-393. PubMed ID: 29227568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
    Tanaka A; Nakamura T; Sato E; Node K
    Drugs R D; 2017 Mar; 17(1):97-101. PubMed ID: 28074335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
    Wakita M; Asai K; Kubota Y; Koen M; Shimizu W
    J Nippon Med Sch; 2021 Nov; 88(5):423-431. PubMed ID: 33455978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
    Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
    Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.
    Ito H; Antoku S; Abe M; Omoto T; Shinozaki M; Nishio S; Mifune M; Togane M; Nakata M; Yamashita T
    Intern Med; 2016; 55(22):3247-3256. PubMed ID: 27853065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors.
    Shimo T; Moto M; Ashizawa N; Matsumoto K; Iwanaga T; Saito K
    Arch Toxicol; 2014 Apr; 88(4):1035-42. PubMed ID: 24448833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibitors of xanthine oxidoreductase].
    Okamoto K
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Iwanaga T; Saitoh K
    J Pharm Pharmacol; 2016 Jan; 68(1):76-83. PubMed ID: 26589240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
    Polito L; Bortolotti M; Battelli MG; Bolognesi A
    Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.